Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

I. Nicol Ferrier; Gareth W. Roberts; Timothy J. Crow; Eve C. Johnstone; David G.C. Owens; Ying C. Lee; David O'Shaughnessy; Tom E. Adrian; Julia M. Polak; Stephen R. Bloom

doi:10.1016/0024-3205(83)90797-X

Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

I. Nicol Ferrier, Gareth W. Roberts, Timothy J. Crow, Eve C. Johnstone, David G.C. Owens, Ying C. Lee, David O'Shaughnessy, Tom E. Adrian, Julia M. Polak, Stephen R. Bloom

Research output: Contribution to journal › Article › peer-review

148 Citations (Scopus)

Abstract

Cholecystokinin-like immunoreactivity (CCK) and somatostatin-like immunoreactivity (SRIF) were determined in fourteen brains from patients dying with a diagnosis of schizophrenia and in twelve brains from control cases. The schizophrenics had been rated during life and were divided into two groups on the basis of the presence or absence of negative symptoms (affective flattening and poverty of speech). CCK was reduced in temporal cortex of the schizophrenics and in hippocampus and amygdala of those patients with negative symptoms. SRIF was reduced in the hippocampus in samples from the latter group. The selectivity of these changes to limbic lobe may reflect the presence of a degenerative process in that area. The association of changes in hippocampus and amygdala with negative symptoms of schizophrenia suggests a separate mechanism underlying these symptoms.

Original language	English
Pages (from-to)	475-482
Number of pages	8
Journal	Life Sciences
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/0024-3205(83)90797-X
Publication status	Published - Aug 1 1983
Externally published	Yes

ASJC Scopus subject areas

General Pharmacology, Toxicology and Pharmaceutics
General Biochemistry,Genetics and Molecular Biology

Access to Document

10.1016/0024-3205(83)90797-X

Cite this

Nicol Ferrier, I., Roberts, G. W., Crow, T. J., Johnstone, E. C., Owens, D. G. C., Lee, Y. C., O'Shaughnessy, D., Adrian, T. E., Polak, J. M., & Bloom, S. R. (1983). Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sciences, 33(5), 475-482. https://doi.org/10.1016/0024-3205(83)90797-X

@article{b9e8a435e7314b53b90096298ee0339a,

title = "Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia",

abstract = "Cholecystokinin-like immunoreactivity (CCK) and somatostatin-like immunoreactivity (SRIF) were determined in fourteen brains from patients dying with a diagnosis of schizophrenia and in twelve brains from control cases. The schizophrenics had been rated during life and were divided into two groups on the basis of the presence or absence of negative symptoms (affective flattening and poverty of speech). CCK was reduced in temporal cortex of the schizophrenics and in hippocampus and amygdala of those patients with negative symptoms. SRIF was reduced in the hippocampus in samples from the latter group. The selectivity of these changes to limbic lobe may reflect the presence of a degenerative process in that area. The association of changes in hippocampus and amygdala with negative symptoms of schizophrenia suggests a separate mechanism underlying these symptoms.",

author = "{Nicol Ferrier}, I. and Roberts, {Gareth W.} and Crow, {Timothy J.} and Johnstone, {Eve C.} and Owens, {David G.C.} and Lee, {Ying C.} and David O'Shaughnessy and Adrian, {Tom E.} and Polak, {Julia M.} and Bloom, {Stephen R.}",

note = "Funding Information: We thank the psychiatrists and pathologists for obtaining the tissue, especially Prof. D. Hume Adams, Dr. R.M. McCreadie, Dr. A. Price and Dr. G. Slavin, and Dr. C.C. Booth for encouraging this collaborative project. We are grateful to Mr. R. Lofthouse, Mr. G. Locker and the administrative, medical and nursing staff of Shenley Hospital, Herts for their assistance in collecting and storing this material. We thank Dr. C.D. Frith for statistical advice. The support of the Wellcome Trust (INF) and of the MRC is gratefully acknowledged,",

year = "1983",

month = aug,

day = "1",

doi = "10.1016/0024-3205(83)90797-X",

language = "English",

volume = "33",

pages = "475--482",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

AU - Nicol Ferrier, I.

AU - Roberts, Gareth W.

AU - Crow, Timothy J.

AU - Johnstone, Eve C.

AU - Owens, David G.C.

AU - Lee, Ying C.

AU - O'Shaughnessy, David

AU - Adrian, Tom E.

AU - Polak, Julia M.

AU - Bloom, Stephen R.

N1 - Funding Information: We thank the psychiatrists and pathologists for obtaining the tissue, especially Prof. D. Hume Adams, Dr. R.M. McCreadie, Dr. A. Price and Dr. G. Slavin, and Dr. C.C. Booth for encouraging this collaborative project. We are grateful to Mr. R. Lofthouse, Mr. G. Locker and the administrative, medical and nursing staff of Shenley Hospital, Herts for their assistance in collecting and storing this material. We thank Dr. C.D. Frith for statistical advice. The support of the Wellcome Trust (INF) and of the MRC is gratefully acknowledged,

PY - 1983/8/1

Y1 - 1983/8/1

N2 - Cholecystokinin-like immunoreactivity (CCK) and somatostatin-like immunoreactivity (SRIF) were determined in fourteen brains from patients dying with a diagnosis of schizophrenia and in twelve brains from control cases. The schizophrenics had been rated during life and were divided into two groups on the basis of the presence or absence of negative symptoms (affective flattening and poverty of speech). CCK was reduced in temporal cortex of the schizophrenics and in hippocampus and amygdala of those patients with negative symptoms. SRIF was reduced in the hippocampus in samples from the latter group. The selectivity of these changes to limbic lobe may reflect the presence of a degenerative process in that area. The association of changes in hippocampus and amygdala with negative symptoms of schizophrenia suggests a separate mechanism underlying these symptoms.

AB - Cholecystokinin-like immunoreactivity (CCK) and somatostatin-like immunoreactivity (SRIF) were determined in fourteen brains from patients dying with a diagnosis of schizophrenia and in twelve brains from control cases. The schizophrenics had been rated during life and were divided into two groups on the basis of the presence or absence of negative symptoms (affective flattening and poverty of speech). CCK was reduced in temporal cortex of the schizophrenics and in hippocampus and amygdala of those patients with negative symptoms. SRIF was reduced in the hippocampus in samples from the latter group. The selectivity of these changes to limbic lobe may reflect the presence of a degenerative process in that area. The association of changes in hippocampus and amygdala with negative symptoms of schizophrenia suggests a separate mechanism underlying these symptoms.

UR - http://www.scopus.com/inward/record.url?scp=0020614092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020614092&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(83)90797-X

DO - 10.1016/0024-3205(83)90797-X

M3 - Article

C2 - 6135969

AN - SCOPUS:0020614092

SN - 0024-3205

VL - 33

SP - 475

EP - 482

JO - Life Sciences

JF - Life Sciences

IS - 5

ER -

Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this